Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Stock Chart & Stats
$52.05
-$0.55(-1.77%)
At close: 4:00 PM EST
$52.05
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$14.80 - $57.88
Previous Close$30.46
Volume740.02K
Average Volume (3M)1.16M
Market Cap
$4.20B
Enterprise Value$4.16B
Total Cash (Recent Filing)$680.26M
Total Debt (Recent Filing)$7.24M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Mar 27, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding80,666,176
10 Day Avg. Volume1,214,540
30 Day Avg. Volume1,159,780
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)2.44
Price to Sales (P/S)1573.67
P/FCF Ratio-22.70
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.91K
Enterprise Value/Gross Profit9.43K
Enterprise Value/Ebitda-25.23
Forecast
1Y Price Target
$77.67Price Target Upside49.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.61
Revenue Forecast (FY)$26.08M
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesRapid trial enrollment and an accelerated pivotal topline readout increase the likelihood of an early efficacy signal that could clarify labeling and attract investor interest.
Commercial ReadinessScaling manufacturing capacity and initiating pre‑launch commercial and payer engagement position the company to meet demand quickly if regulatory approval is achieved.
Regulatory And Label PotentialStudying the therapy across the full intermediate‑risk non‑muscle invasive bladder cancer spectrum could support a broad label and expand the addressable patient population beyond high‑risk settings.
Bears Say
Clinical Adoption RiskUncertainty about long‑term durability of responses could limit physician adoption and constrain commercial uptake even if initial efficacy and safety data look favorable.
Event-driven VolatilityThe added pivotal trial readout concentrates event-driven risk, so disappointing results could trigger sharp share declines and heightened market volatility.
Financing RiskEstimated cash burn relative to available cash points to potential financing pressure if clinical or commercial progress is slower than expected, increasing dilution risk for shareholders.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $14.80 and its highest was $57.88 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $4.20B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 53 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Nov 14, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$0.011.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.6.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 80,666,176 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 8.607%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.67 (49.22% Upside)
$77.67 (49.22% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 57.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 21.5%
Last 30 Days ▲ 21.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.63%
12-Months-Change
Fundamentals
Return on Equity
-24.74%
Trailing 12-Months
Asset Growth
32.12%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$77.67
▲(49.22% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.61% Insiders
23.54% Mutual Funds
0.03% Other Institutional Investors
50.92% Public Companies and
Individual Investors